SCHEMBL20932763

SCHEMBL20932763

FC(F)(F)c1ccc(CCN2CN=C(SCc3ccccc3CSC3=NCN(CCc4ccc(C(F)(F)F)cc4)CN3)NC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ TOP2A P11388 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ DAO P14920 1/20 0.39
▸ ADRA1D P25100 1/20 0.39
▸ ADRA1A P35348 1/20 0.39
▸ ADRA1B P35368 1/20 0.39
▸ GPR84 Q9NQS5 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ ALOX15B O15296 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ SCN9A Q15858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20917797 0.91 MAPT (0.47) MAPTALDH1A1CYP2C19SMN1; SMN2TSHR
SCHEMBL20920201 0.90 KDM4E (0.41) MAPTALDH1A1TOP2ATSHRCYP3A4
SCHEMBL22275610 0.88 PPARD (0.38) MAPTALDH1A1CYP2C19TOP2ASMN1; SMN2
SCHEMBL22262985 0.88 GPR84 (0.38) MAPTALDH1A1CYP2C19TOP2ASMN1; SMN2
SCHEMBL20917798 0.87 SLC6A4 (0.36) MAPTALDH1A1CYP2C19SMN1; SMN2TSHR
SCHEMBL22263183 0.87 ALDH1A1 (0.53) ALDH1A1CYP2C19SMN1; SMN2TSHRMAPK1
SCHEMBL20932777 0.85 TAAR1 (0.45) ALDH1A1CYP2C19SMN1; SMN2TSHRGAA
SCHEMBL20920797 0.85 ALDH1A1 (0.44) ALDH1A1CYP2C19SMN1; SMN2TSHRMAPK1
SCHEMBL20917919 0.85 ALDH1A1 (0.44) MAPTALDH1A1CYP2C19SMN1; SMN2TSHR
SCHEMBL20917786 0.81 ALOX15B (0.46) MAPTALDH1A1MAPK1MAOBALOX15B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12209079-B2 IDO/TDO inhibitor GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2025-01-28 — — US disclosed
US-20200239452-A1 IDO/TDO Inhibitor CANBAS CO., LTD. (JP) 2020-07-30 — — US disclosed
WO-2019078246-A1 IDO/TDO INHIBITOR 一般社団法人ファルマバレープロジェクト支援機構 2019-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209079-B2 IDO/TDO inhibitor IDO1, IDO2, TDO2 MAPT 609/4885ALDH1A1 3331/4885CYP2C19 573/4885
US-20200239452-A1 IDO/TDO Inhibitor IDO1, IDO2, TDO2 MAPT 609/4885ALDH1A1 3331/4885CYP2C19 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback